相关实验视频
Updated: Sep 20, 2025
05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
6.8K
塞马格卢提德给药对腹手术后减肥的影响:一个元分析
Tannaz Jamialahamdi1, Elaheh Mirhadi2, Wael Almahmeed3
1Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Obesity surgery
|May 26, 2025
概括
塞马格卢提德有效地帮助减肥的患者经历体重增加或不足的减肥后减肥手术. 这一系统性审查证实了其在减肥术后应对体重挑战方面的有效性.
科学领域:
- 腹部外科手术的结果
- 对肥胖的药理干预措施
背景情况:
- 腹部外科手术后的重量恢复 (WG) 或不充分的减肥 (IWL) 影响了许多患者.
- 塞马格卢提德正在被研究为管理体重挑战后腹手术.
- 缺乏关于塞马格卢提德在这个人群中的疗效的系统审查和元分析.
研究的目的:
- 系统地审查和分析WG或IWL患者在减肥手术后的塞马格卢提德的疗效,安全性和耐受性.
主要方法:
- 搜索了RCT,病例控制,队列和观察研究的数据库.
- 包括在干预手臂的腹部外科手术后使用塞马格卢提德的研究.
- 主要结局是减肥后的减肥手术.
主要成果:
- 分析了6项涉及300名参与者的研究.
- 在腹部外科手术后,塞马格卢提德显著减轻了体重 (WMD: -15.730,p < 0.001).
- 在敏感性分析中,观察到的效果是强大的.
结论:
- 目前的证据支持在减肥手术后使用西马格卢提德来管理体重增加或体重不足.
- 塞马格卢提德显示为这个患者群体的治疗选择有前途.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
313
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
313
01:24Glucagon-like Receptor Agonists
443
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
443
01:21Inflammatory Bowel Disease V: Surgical Management
226
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
226
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
278